News

AstraZeneca has modified an existing agreement with the US Government to supply up to 500,000 additional doses of AZD7442, a long-acting antibody (LAAB) combination which is in…
Read More...

Moderna Inc. a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announced that the first participants have been dosed in the Phase 2/3 study, called the…
Read More...

WuXi Biologics announced that it has entered into an equity agreement with Pfizer China to acquire its state-of-the-art biologics manufacturing facilities as well as its labor force in…
Read More...

Nurix Therapeutics, Inc. a biopharmaceutical company developing targeted protein modulation drugs,  announced that it is part of a collaboration sponsored by Alex’s Lemonade Stand…
Read More...

Ampio Pharmaceuticals a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, recently revealed preliminary positive…
Read More...

Takeda Pharmaceutical Company Limited announced a mutual agreement with IDT Biologika GmbH, a contract development and manufacturing organization, to utilize capacity at IDT previously…
Read More...

Gilead Sciences, Inc. and Merck, known as MSD outside the United States and Canada, today announced that they have entered into an agreement to co-develop and co-commercialize…
Read More...

Novartis announced new data that reinforce the transformational benefit of Zolgensma (onasemnogene abeparvovec), an essential one-time treatment for spinal muscular atrophy (SMA). The…
Read More...

Aurinia Pharmaceuticals Inc. announced a favorable assessment regarding the cost-effectiveness and value of LUPKYNIS (voclosporin), based on an independent analysis issued by the…
Read More...

HepaTx Corporation, Namocell Inc., and Takara Bio USA, Inc. (TBUSA) announced successful completion of the second phase of their collaboration on single cell analysis of hepatocyte-like…
Read More...

Novavax, Inc. a biotechnology company developing next-generation vaccines for serious infectious diseases, announced final efficacy of 96.4% against mild, moderate and severe disease…
Read More...

PhaseBio Pharmaceuticals, Inc. a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, and BioVectra…
Read More...

Orgenesis Inc. a global biotech company working to unlock the full potential of cell and gene therapies,  announces that it has entered the planned second phase of a collaboration with…
Read More...

Complix, a biopharmaceutical company developing a pipeline of transformative Alphabody therapeutics announces that it has signed a significant drug discovery deal with I-Mab, an…
Read More...

CEPI, the Coalition for Epidemic Preparedness Innovations, and VBI Vaccines Inc. announced a partnership to develop VBI’s enveloped virus like particle (eVLP) vaccine candidates against…
Read More...

Enveric Biosciences a patient-first biotechnology company developing novel cannabinoid medicines to improve quality of life for cancer patients, announced that it has acquired an…
Read More...

Sparta Biopharma, Inc., a privately-held company, developing osteobiologics for sports medicine announces the availability of BioEnthesis, the first-of-its-kind allograft that has both…
Read More...

NeuroRx, Inc. and TFF Pharmaceuticals, Inc. are announcing that the companies have entered into a feasibility and material transfer agreement (Feasibility Agreement). Under the…
Read More...

Novartis announced the Phase III CANOPY-2 study evaluating canakinumab (ACZ885), an inhibitor of interleukin-1beta (IL-1β), in combination with the chemotherapy agent docetaxel, did not…
Read More...

Valo Therapeutics Limited (Valo Tx), the developer of novel and adaptable immunotherapy platforms for cancer and infectious diseases, announced the completion of a successful…
Read More...